Semaglutide targets one receptor
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
It is worth noting that the online marketplace for weight-loss medications has expanded considerably in recent years
It represents the companys broader move into next-generation combination biology
This risk may affect treatment continuation in some patients
they also reduce the risk of cardiovascular disease, slow the progression of chronic kidney disease, and improve conditions like sleep apnea, said senior author David Kim, PhD, a health economist at UChicago
